Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>UK embraces Cybin’s PARADIGMTM program.</li><li>As Cybin continues to dose participants with moderate to severe major depressive disorder (MDD) across 45 US- located sites in its first pivotal study (APPROACH) for adjunctive CYB003, the company's preparations for the soon-to-start second pivotal study of the Phase 3 program, EMBRACE, is gathering momentum.</li><li>To this end, Cybin has announced that it has received approval to commence EMBRACE from the UK MHRA (UK Medical and Healthcare Agency).</li></ul>

UK embraces Cybin’s PARADIGMTM program.As Cybin continues to dose participants with moderate to severe major depressive disorder (MDD) across 45 US- located sites in its first pivotal study (APPROACH) for adjunctive CYB003, the company's preparations for the soon-to-start second pivotal study of the Phase 3 program, EMBRACE, is gathering momentum.To this end, Cybin has announced that it has received approval to commence EMBRACE from the UK MHRA (UK Medical and Healthcare Agency).

Cybin Inc: CYB003 Phase 3 Program Continues to Progress on Plan